Global Dopamine Agonists Market Size Grows at a CAGR of 5.41%

Introduction

Straits Research released its highly anticipated report, “Global Dopamine Agonists Market Size & Outlook, 2026-2034.” According to the study, the global market size is valued at USD 1.35 billion in 2025 and is projected to expand to USD 2.16 billion by 2034, registering a compound annual growth rate (CAGR) of 5.41%.

Market Dynamics

The market growth is primarily attributed to the increasing prevalence of neurological disorders such as Parkinson’s disease and restless legs syndrome, the rising aging population, and growing awareness about early diagnosis and effective treatment options. In addition, the broad therapeutic applications of dopamine agonists significantly drive market growth, as these medications are widely utilized across various neurological and endocrine disorders. For instance, in June 2023, as per the National Library of Medicine, ropinirole is considered a first-line treatment for Restless Legs Syndrome (RLS), while bromocriptine is administered for neuroleptic malignant syndrome (NMS). Such diverse indications enhance manufacturers' portfolios, expand revenue potential, and establish a competitive edge in neurology and endocrine treatments. Moreover, with increasing patient demand for convenient dosing, improved adherence, and better management of chronic neurological disorders, such as Parkinson’s disease and restless legs syndrome, pharmaceutical companies have the opportunity to innovate extended-release tablets, transdermal patches, and combination therapies. These novel formulations can enhance treatment outcomes, reduce side effects, and differentiate products in a competitive market, driving both adoption and revenue growth.

Market Highlights

• Indication: The Parkinson’s Disease segment dominated the market in 2025, with a revenue share of 61.94%.
• Drug Type: The Ergot Alkaloids segment is expected to witness the highest CAGR (6.31%) during the forecast period. 
• Route of Administration: The Oral segment dominated the market in 2025 with a revenue share of 55.62%, owing to its ease of self-administration and higher patient compliance.
• Distribution Channel: The Drug Stores & Retail Pharmacies segment is expected to witness the highest CAGR (5.98%) during the forecast period.
• Regional Insights: North America dominates the market in 2025 with a 14% share, fuelled by the accessibility of advanced therapies.

Competitive Players

1. Teva Pharmaceutical Industries Ltd
2. Supernus Pharmaceuticals
3. Lundbeck A/S
4. AbbVie Inc.
5. Novartis AG
6. Amneal Pharmaceuticals LLC
7. Reddy’s Laboratories Ltd
8. Intas Pharmaceuticals Ltd.
9. GLENMARK PHARMACEUTICALS LTD.
10. Zydus Group
11. Hikma Pharmaceuticals PLC
12. TORRENT PHARMACEUTICALS LTD.
13. Apotex Inc.
14. Alto Neuroscience, Inc.
15. Mylan N.V.
16. Kyowa Kirin Co., Ltd.
17. Neurocrine Biosciences, Inc.,
18. Acorda Therapeutics, Inc.
19. Acadia Pharmaceuticals Inc.
20. Hoffmann-La Roche Ltd 
21. Others

Recent Developments

Segmentation

1. By Indication (2026-2034)
   1. Parkinson's disease
   2. Restless legs syndrome
   3. Hyperprolactinemia
   4. Others
2. By Drug Type (2026-2034)
   1. Ergot Alkaloids
   2. Non-Ergot Dopamine Agonists
3. By Route of Administration (2026-2034)
   1. Oral
   2. Injectable
   3. Others
4. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Drug Stores & Retail Pharmacies
   3. Other Pharmacies